Submission of standalone un-audited financial statements for the quarter ended 30.06.2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) reported zero revenue from operations for Q1 FY26, with total income of just Rs 0.40 lakhs from other income. The company posted a net loss of Rs 22.01 lakhs, similar to the Rs 22.24 lakhs loss in the year-ago quarter. Cumulative losses for FY25 stood at Rs 89.79 lakhs. The company has applied for renewal of its drug manufacturing licences with the FDA Panchkula and is exploring new business opportunities. The statutory auditor issued a qualified conclusion, flagging untraceable investment certificates worth Rs 53.80 lakhs and stalled capital work-in-progress of Rs 2.91 crore. Listing fees to BSE for F.Y. 2021-22 to 2024-25 remain unpaid, with action initiated against the company.
The company is essentially non-operational with no sales, continued quarterly losses of over Rs 22 lakhs, and unresolved regulatory/license issues — a serious red flag for shareholders. The qualified audit opinion, emphasis of matter on zero revenue, and unpaid listing fees signal significant operational and compliance distress.